Fattahi Z, Kalhor Z, Fadaee M, Vazehan R, Parsimehr E, Abolhassani A, Beheshtian M, Zamani G, Nafissi S, Nilipour Y, Akbari M R, Kahrizi K, Kariminejad A, Najmabadi H
Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
Kariminejad - Najmabadi Pathology & Genetics Center, Tehran, Iran.
Clin Genet. 2017 Mar;91(3):386-402. doi: 10.1111/cge.12810. Epub 2016 Jul 21.
Neuromuscular diseases (NMDs) include a broad range of disorders affecting muscles, nerves and neuromuscular junctions. Their overlapping phenotypes and heterogeneous genetic nature have created challenges in diagnosis which calls for the implementation of massive parallel sequencing as a candidate strategy to increase the diagnostic yield. In this study, total of 45 patients, mostly offspring of consanguineous marriages were examined using whole exome sequencing. Data analysis was performed to identify the most probable pathogenic rare variants in known NMD genes which led to identification of causal variants for 33 out of 45 patients (73.3%) in the following known genes: CAPN3, Col6A1, Col6A3, DMD, DYSF, FHL1, GJB1, ISPD, LAMA2, LMNA, PLEC1, RYR1, SGCA, SGCB, SYNE1, TNNT1 and 22 novel pathogenic variants were detected. Today, the advantage of whole exome sequencing in clinical diagnostic strategies of heterogeneous disorders is clear. In this cohort, a diagnostic yield of 73.3% was achieved which is quite high compared to the overall reported diagnostic yield of 25% to 50%. This could be explained by the consanguineous background of these patients and is another strong advantage of offering clinical exome sequencing in diagnostic laboratories, especially in populations with high rate of consanguinity.
神经肌肉疾病(NMDs)包括一系列影响肌肉、神经和神经肌肉接头的疾病。它们重叠的表型和异质的遗传性质给诊断带来了挑战,这就需要采用大规模平行测序作为一种候选策略来提高诊断率。在本研究中,共对45名患者进行了全外显子组测序,其中大多数是近亲结婚的后代。通过数据分析来确定已知NMD基因中最可能的致病性罕见变异,这使得在以下已知基因中为45名患者中的33名(73.3%)鉴定出了致病变异:钙蛋白酶3(CAPN3)、胶原蛋白6A1(Col6A1)、胶原蛋白6A3(Col6A3)、抗肌萎缩蛋白(DMD)、肌营养不良蛋白聚糖(DYSF)、四半LIM结构域蛋白1(FHL1)、间隙连接蛋白β1(GJB1)、整合素结合蛋白(ISPD)、层粘连蛋白α2(LAMA2)、核纤层蛋白A/C(LMNA)、斑联蛋白1(PLEC1)、兰尼碱受体1(RYR1)、α-肌动蛋白(SGCA)、β-肌动蛋白(SGCB)、核膜蛋白1(SYNE1)、肌钙蛋白T1(TNNT1),并检测到22种新的致病变异。如今,全外显子组测序在异质性疾病临床诊断策略中的优势已很明显。在这个队列中,诊断率达到了73.3%,与总体报道的25%至50%的诊断率相比相当高。这可以用这些患者的近亲背景来解释,这也是诊断实验室提供临床外显子组测序的另一个显著优势,尤其是在近亲结婚率高的人群中。